

**Vectura Group plc**

**Results of the Annual General Meeting held on 23 September 2009**

**Chippenham, UK, 23 September 2009:** Vectura Group plc (LSE: VEC) announces that all resolutions proposed to shareholders at its Annual General Meeting held today were duly passed by shareholders.

All resolutions were approved on a poll. The results of the poll are set out below.

Resolution	Total votes for (including discretionary votes)*	%	Total votes against*	%	Total votes cast (excluding votes withheld)	Votes withheld
1 To receive the Report & Accounts	240,263,851	99.32	1,634,662	0.68	241,898,513	155
2 To re-elect Dr Chris Blackwell	241,644,041	99.90	244,587	0.10	241,888,628	10,040
3 To re-elect Dr Andrew Richards	231,861,593	98.28	4,047,100	1.72	235,908,693	5,989,975
4 To re-appoint Deloitte LLP	241,887,634	99.99	10,678	0.01	241,898,312	356
5 To approve the Report on Directors' Remuneration	218,017,364	91.38	20,559,266	8.62	238,576,630	3,322,038
6 To renew the Directors' authority to allot shares	241,828,640	99.97	62,367	0.03	241,891,007	7,661
7 To renew the Directors' authority to allot shares for cash	218,194,153	94.78	12,024,620	5.22	230,218,773	11,679,895
8 To authorise the Directors' authority to call general meetings	241,631,377	99.89	264,298	0.11	241,895,675	2,993

\*NB: The percentage of votes cast for and against excludes withheld votes.

Copies of the approved resolutions will be submitted to the UK Listing Authority and will shortly be available for inspection at the UK Listing Authority's Document Viewing facility, which is situated at:

Financial Services Authority  
25 The North Colonnade  
Canary Wharf  
London E14 5HS  
Tel: +44 (0)20 7676 1000

– Ends –

**Enquiries:****Vectura Group plc**

Chris Blackwell, Chief Executive  
Anne Hyland, Chief Financial Officer  
Julia Wilson, Director of Investor Relations

+44 (0)1249 667700

**Financial Dynamics**

Ben Atwell  
Susan Quigley

+44 (0)20 7831 3113

**Notes for Editors:****About Vectura**

Vectura Group plc is a product-focused Group that develops inhaled therapies principally for the treatment of respiratory diseases. Vectura's main products target diseases such as asthma and chronic obstructive pulmonary disease (COPD); a growing market that is currently estimated to be worth \$20 billion. Vectura also develops products for other lung pathologies and non-respiratory diseases.

Vectura has eight products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development, some of which have been licensed to major pharmaceutical companies. Vectura seeks to develop certain programmes itself where this will optimise value. Vectura's formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy.

Vectura has development collaborations with several pharmaceutical companies, including Boehringer Ingelheim, Novartis, Sandoz (the generics arm of Novartis), Baxter, GlaxoSmithKline (GSK), Mylan, UCB and Otsuka. Vectura has been included in the FTSE 250 index since 23 March 2009. For further information, please visit Vectura's website at [www.vectura.com](http://www.vectura.com)